1.55
Schlusskurs vom Vortag:
$1.57
Offen:
$1.58
24-Stunden-Volumen:
31,757
Relative Volume:
1.71
Marktkapitalisierung:
$63.74M
Einnahmen:
$1.88M
Nettoeinkommen (Verlust:
$-16.06M
KGV:
-7.8362
EPS:
-0.1978
Netto-Cashflow:
$-50.09M
1W Leistung:
+19.77%
1M Leistung:
-9.38%
6M Leistung:
-26.08%
1J Leistung:
-9.12%
Beyondspring Inc Stock (BYSI) Company Profile
Firmenname
Beyondspring Inc
Sektor
Branche
Telefon
646-528-4184
Adresse
100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR, FLORHAM PARK, NY
Compare BYSI vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
BYSI
Beyondspring Inc
|
1.55 | 64.56M | 1.88M | -16.06M | -50.09M | -0.1978 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.69 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.59 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
806.19 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
294.62 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
154.32 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-12-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-02 | Herabstufung | Jefferies | Buy → Hold |
| 2021-12-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-12-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-09-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-08-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-04-05 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-01-11 | Eingeleitet | BofA Securities | Buy |
| 2020-12-29 | Eingeleitet | Evercore ISI | Outperform |
| 2020-02-07 | Eingeleitet | Jefferies | Buy |
| 2020-01-10 | Eingeleitet | Nomura | Buy |
| 2019-12-03 | Eingeleitet | William Blair | Outperform |
| 2019-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-30 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-10-25 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Beyondspring Inc Aktie (BYSI) Neueste Nachrichten
BYSI Q1 2026 Earnings: Narrow Loss and Modest Stock Gain as Pipeline Progress ContinuesMid-Term Outlook - Newser
BeyondSpring Q1 2026 Earnings: Narrowing Loss Highlights Pipeline Progress Amid Zero RevenueTrending Buy Opportunities - Newser
BeyondSpring Inc. to Present Study 303 on Plinabulin Combination Therapy for NSCLC at ASCO 2026 - Quiver Quantitative
Phase 2 plinabulin combo in resistant NSCLC to appear at 2026 ASCO - Stock Titan
BYSI BeyondSpring beats Q4 EPS estimates by 11 but shares drop 25 on zero revenueValue Pick - Newser
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting - Yahoo Finance
Number of shareholders of BeyondSpring, Inc. – NASDAQ:BYSI - TradingView
Lan Huang trust gifts 260,582 BeyondSpring (BYSI) shares in Form 4 filing - Stock Titan
BeyondSpring (BYSI) insiders report 14.1% each; trust transfers disclosed - Stock Titan
BeyondSpring Reports Q1 2026 Financial Results: Plinabulin Pipeline Progress and SEED Therapeutics Clinical Update - Minichart
BeyondSpring Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BeyondSpring (NASDAQ: BYSI) swings to $6.7M net loss as SEED ops weigh - Stock Titan
BeyondSpring Releases Q1 2026 Financial Results - AlphaStreet
BeyondSpring (BYSI) Q1 2026 Results: EPS -$0.05, Revenue $0 -- H - GuruFocus
BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI) - Yahoo Finance
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
BeyondSpring stock gains 6% on narrower loss, pipeline progress By Investing.com - Investing.com South Africa
BeyondSpring stock gains 6% on narrower loss, pipeline progress - Investing.com
BeyondSpring Inc. (BYSI) Reports Q1 Loss of $0.06 - StreetInsider
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
BeyondSpring reports Q1 2026 results: $2.4M continuing net loss, $7.9M cash & short-term investments - TradingView
BeyondSpring (BYSI) posts Q1 2026 net loss as ADC and molecular glue programs advance - Stock Titan
TradingKey - TradingKey
BYSI (BeyondSpring) Q4 loss narrows ahead of estimates despite zero revenue, but shares slip 2.54%.Special Situation - newser.com
Why BeyondSpring (BYSI) might be the portfolio Builder you need (Momentum Fading) 2026-05-08Verified Stock Signals - Newser
BeyondSpring (BYSI) to Release Quarterly Earnings on Tuesday - MarketBeat
BYSI BeyondSpring Q4 2021 EPS exceeds analyst expectations but shares drop 1.99 percent in today’s session.Most Discussed Stocks - newser.com
BeyondSpring (NASDAQ:BYSI) Stock Price Passes Below Fifty Day Moving AverageTime to Sell? - MarketBeat
Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth? - Sahm
BeyondSpring (NASDAQ:BYSI) Stock Price Up 0.1%Here's Why - MarketBeat
BYSI (BeyondSpring Inc. Ordinary Shares) posts narrower than expected Q4 2021 loss, shares rise nearly 3 percent on positive market reception.Beat Estimates - Cổng thông tin điện tử Tỉnh Sơn La
BeyondSpring : Corporate Presentation - marketscreener.com
BeyondSpring reports preclinical data on plinabulin-ADC combos - Investing.com
BeyondSpring reports preclinical data on plinabulin-ADC combos By Investing.com - Investing.com South Africa
BeyondSpring presents preclinical data on Plinabulin ADC combinations - StreetInsider
Cancer-drug combo cut animal deaths and extended survival in AACR study - Stock Titan
Recap Report: Whats the RSI of BeyondSpring Inc stock2026 Fed Impact & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Is BeyondSpring Inc exposed to political risk2026 Drop Watch & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Quarterly Earnings: Can BeyondSpring Inc maintain sales growth2026 Final Week & Precise Buy Zone Identification - baoquankhu1.vn
BeyondSpring Reports 2025 Year-End Financial Results - ADVFN
Are investors bullish on BeyondSpring (BYSI) Stock | Price at $1.82, Up 2.77%Crowd Trend Signals - Newser
What is the long-term potential of BeyondSpring (BYSI) Stock | Price at $1.82, Up 3.58%Stock Accumulation - Newser
BeyondSpring (BYSI) director awarded 23,902 stock options at $1.64 strike price - Stock Titan
Pullback Watch: Can BeyondSpring Inc beat the S P 500Weekly Stock Report & AI Forecasted Stock Moves - baoquankhu1.vn
Here's Why We're A Bit Worried About BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation - Yahoo Finance
Is BeyondSpring (BYSI) Stock Undervalued Now | Price at $1.75, Up 2.34%Social Buy Zones - Newser
BeyondSpring (NASDAQ:BYSI) Stock Passes Above 50 Day Moving Average – Here’s Why - Defense World
BYSI PE Ratio & Valuation, Is BYSI Overvalued - Intellectia AI
BeyondSpring Stock Crosses 50-Day Moving Average - National Today
BeyondSpring (NASDAQ:BYSI) Stock Crosses Above 50 Day Moving AverageShould You Sell? - MarketBeat
BeyondSpring (BYSI) director receives 22,165 stock options grant - Stock Titan
Finanzdaten der Beyondspring Inc-Aktie (BYSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Beyondspring Inc-Aktie (BYSI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Decheng Capital China Life Sci | 10% Owner |
Oct 17 '25 |
Sale |
1.76 |
45,513 |
80,103 |
1,518,893 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 13 '25 |
Sale |
1.70 |
107,361 |
182,514 |
1,696,659 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 14 '25 |
Sale |
1.65 |
28,495 |
47,017 |
1,668,164 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 15 '25 |
Sale |
1.65 |
17,960 |
29,634 |
1,650,204 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 08 '25 |
Sale |
1.77 |
7,507 |
13,287 |
1,810,389 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 09 '25 |
Sale |
1.81 |
3,979 |
7,202 |
1,806,410 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 10 '25 |
Sale |
1.77 |
2,390 |
4,230 |
1,804,020 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 06 '25 |
Sale |
1.78 |
17,500 |
31,150 |
1,819,996 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 07 '25 |
Sale |
1.79 |
2,100 |
3,759 |
1,817,896 |
| Decheng Capital China Life Sci | 10% Owner |
Oct 03 '25 |
Sale |
1.76 |
600 |
1,056 |
1,837,496 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):